ClinicalTrials.gg
CompletedNCT05308472Updated Jan 8, 2026Results posted

Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPP

A Phase 2 interventional study of DISC-1459 and DISC-1459 in Erythropoietic Protoporphyria, sponsored by Disc Medicine, Inc. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Disc Medicine, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Protoporphyria, Erythropoietic with a site in United States — 4 open to participants now, 4 under way, 2 of them phase 3. Protoporphyria, Erythropoietic · United States.

Enrollment
8th of 13
75 · median 77
Started
2022
with 1 other
Phase 2
5 of 18
none open now
Registered
11th of 18
by date
Lead sponsor
4 of 18
Disc Medicine, Inc

Among the 18 studies in Protoporphyria, Erythropoietic with a site in United States, this one is the 8th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 in phase 2, and was the 11th registered.

Protoporphyria, Erythropoietic

29 studies on the registry are indexed under Protoporphyria, Erythropoietic; 5 are open to participants now.

Browse Protoporphyria, Erythropoietic studies →

Open to participants now

4 of the 18 studies in Protoporphyria, Erythropoietic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Protoporphyria, Erythropoietic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Protoporphyria, Erythropoietic with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multi-center, double-blind, placebo-controlled, parallel group study of bitopertin to evaluate the safety, tolerability, efficacy, and PPIX concentration change in participants with EPP. Participants may roll over to an open label extension portion after completing the double-blind treatment period.

03

Conditions studied

  • Erythropoietic Protoporphyria

Keywords

  • EPP
  • DISC-1459
  • RO4917838
  • porphyria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years or older at the time of signing the form (ICF).
  2. Diagnosis of EPP, based on medical history by ferrochelatase ( FECH) genotyping or by biochemical porphyrin analysis.
  3. Body weight ≥50 kg.
  4. of at least 2 months prior to Screening of afamelanotide and dersimelagon, if applicable.
  5. (AST) and alanine transaminase (ALT) \<2× (ULN) and total \<ULN (unless documented Gilbert syndrome) at Screening. Albumin >lower limit of normal (LLN).

Exclusion criteria

Exclusion Criteria:

Medical History:

  1. Major surgery within 8 weeks before Screening or incomplete recovery from any previous surgery.
  2. Other than EPP, an inherited or acquired red cell disease associated with anemia.
  3. A history or known allergic reaction to any product or history of anaphylaxis to any food or drug.
  4. History of liver transplantation.
  5. History of alcohol dependence or excessive alcohol consumption, as assessed by the Investigator.
  6. (HIV), active , or C.
  7. Other medical or psychiatric condition or laboratory finding not specifically noted above that, in the judgment of the Investigator or Sponsor, would put the participant at unacceptable risk or otherwise preclude the participant from participating in the study
  8. Condition or concomitant medication that would confound the ability to interpret clinical, clinical laboratory, or participant diary data, including a major psychiatric condition that has had an exacerbation or required hospitalization in the last 6 months.

    Treatment History:

  9. Concurrent or planned treatment with afamelanotide or dersimelagon during the study period.
  10. Treatment with opioids for any period >7 days in the 2 months prior to screening or anticipated to require opioid use for >7 days at any point during the study.
  11. New treatment for anemia, including initiation of iron supplementation, in the 2 months prior to Screening.
  12. Current or planned use of any drugs or herbal remedies known to be strong inhibitors or inducers of enzymes for 28 days prior to the first dose and throughout the study.

    Laboratory Exclusions:

  13. \<10 g/dL at Screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    DISC-1459 oral dose level 1

    Drug: DISC-1459

  • Experimental
    DISC-1459 oral dose level 2

    Drug: DISC-1459

Interventions

  • Oral dose level 1, once a day for 120 days

    Also known as: Bitopertin, RO4917838

  • Oral dose level 2, once a day for 120 days

    Also known as: Bitopertin, RO4917838

  • DrugPlacebo

    Oral dose, once a day for 120 days

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Whole Blood Metal-free PPIX Levels

    Percent change from baseline in PPIX concentration was analyzed using a mixed model repeated measures analysis in the ITT population.

    Time frame: 121 days

Secondary outcomes

  1. Total Hours of Sunlight Exposure to Skin on Days With no Pain From 1000 to 1800 Hours (10:00am to 6:00pm)

    Cumulative total hours of sunlight exposure on days with no pain from 1000 to 1800 hours from baseline to Day 121 (EOS) was analyzed using analysis of variance in the ITT population.

    Time frame: 121 days

  2. Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post-sunrise and 1 Hour Pre-sunset

    Participants exposed their skin to sunlight once a week and measured the time it takes to experience a prodrome. The time (minutes) to first prodromal symptom (e.g., burning, tingling, itching, or stinging) associated with sunlight exposure was recorded in a diary. This sun exposure challenge was performed weekly. The average time (minutes) to first prodromal symptom (e.g., burning, tingling, itching, or stinging) associated with sunlight exposure was averaged over two-week intervals through Study Day 121.

    Time frame: 121 days

  3. Total Pain Intensity

    The maximum total daily pain intensity scores of phototoxic reactions over the entire treatment period (D1-D121). The maximum pain score of a phototoxic reaction was measured on a Likert Scale (0-10). Total scores range from 0-1210. A score of "0" is the best outcome; and higher scores are a worse outcome. The maximum pain values on a scale of 0-10 in a day were summed across 121 days.

    Time frame: Sum of Day 1 to Day 121

  4. Incidence of Treatment-emergent Adverse Events

    Incidence of treatment-emergent adverse events

    Time frame: 121 days

  5. Erythrocyte Total PPIX Concentrations

    Percent change from baseline in erythrocyte total PPIX concentration was summarized by analysis visit in the ITT population.

    Time frame: 121 days

  6. Plasma Total PPIX Concentrations

    Percent change from baseline in plasma total PPIX concentration was summarized by analysis visit in the ITT population.

    Time frame: 121 days

  7. Whole Blood Total PPIX Concentrations

    Percent change from baseline in whole blood total PPIX concentration was summarized by analysis visit in the ITT population.

    Time frame: 121 days

  8. Plasma Bitopertin Concentrations

    Day 29 plasma bitopertin concentrations, 4 hours post-dose

    Time frame: Day 29

07

Results

Posted Jan 8, 2026

Participant flow

Participant flow — Overall Study
MilestonePlaceboDISC-1459 Oral Low DoseDISC-1459 Oral High Dose
Started242625
Completed242622
Not completed003
Withdrew: Adverse event003

Outcome measures

PrimaryPercent Change From Baseline in Whole Blood Metal-free PPIX Levels

Percent change from baseline in PPIX concentration was analyzed using a mixed model repeated measures analysis in the ITT population.

Time frame:
121 days
Reported as:
Mean · Percent Change
Percent Change From Baseline in Whole Blood Metal-free PPIX Levels
Percent ChangePlaceboDISC-1459 Oral Low DoseDISC-1459 Oral High Dose l
Percent Change From Baseline in Whole Blood Metal-free PPIX Levels8.07 (-6.200 to 22.338)-21.48 (-35.842 to -7.125)-41.74 (-56.531 to -26.950)
SecondaryTotal Hours of Sunlight Exposure to Skin on Days With no Pain From 1000 to 1800 Hours (10:00am to 6:00pm)

Cumulative total hours of sunlight exposure on days with no pain from 1000 to 1800 hours from baseline to Day 121 (EOS) was analyzed using analysis of variance in the ITT population.

Time frame:
121 days
Reported as:
Mean · Hours
Total Hours of Sunlight Exposure to Skin on Days With no Pain From 1000 to 1800 Hours (10:00am to 6:00pm)
HoursPlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose Level
Total Hours of Sunlight Exposure to Skin on Days With no Pain From 1000 to 1800 Hours (10:00am to 6:00pm)133.91 (92.180 to 175.643)175.11 (134.723 to 215.489)153.14 (111.699 to 194.585)
SecondaryDaily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post-sunrise and 1 Hour Pre-sunset

Participants exposed their skin to sunlight once a week and measured the time it takes to experience a prodrome. The time (minutes) to first prodromal symptom (e.g., burning, tingling, itching, or stinging) associated with sunlight exposure was recorded in a diary. This sun exposure challenge was performed weekly. The average time (minutes) to first prodromal symptom (e.g., burning, tingling, itching, or stinging) associated with sunlight exposure was averaged over two-week intervals through Study Day 121.

Time frame:
121 days
Reported as:
Mean · Minutes/Two Weeks
Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post-sunrise and 1 Hour Pre-sunset
Minutes/Two WeeksPlaceboDISC-1459 Oral Low DoseDISC-1459 Oral High Dose
Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post-sunrise and 1 Hour Pre-sunset149.05 ± 116.434155.51 ± 99.903176.14 ± 134.952
SecondaryTotal Pain Intensity

The maximum total daily pain intensity scores of phototoxic reactions over the entire treatment period (D1-D121). The maximum pain score of a phototoxic reaction was measured on a Likert Scale (0-10). Total scores range from 0-1210. A score of "0" is the best outcome; and higher scores are a worse outcome. The maximum pain values on a scale of 0-10 in a day were summed across 121 days.

Time frame:
Sum of Day 1 to Day 121
Reported as:
Mean · Scores on a scale
Total Pain Intensity
Scores on a scalePlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose Level
Total Pain Intensity13.0 ± 9.3815.0 ± 13.956.3 ± 2.50
SecondaryIncidence of Treatment-emergent Adverse Events

Incidence of treatment-emergent adverse events

Time frame:
121 days
Reported as:
Count of participants · Participants
Incidence of Treatment-emergent Adverse Events
ParticipantsPlaceboDISC-1459 Oral Low DoseDISC-1459 Oral High Dose
Incidence of Treatment-emergent Adverse Events191922
SecondaryErythrocyte Total PPIX Concentrations

Percent change from baseline in erythrocyte total PPIX concentration was summarized by analysis visit in the ITT population.

Time frame:
121 days
Reported as:
Mean · Percent Change
Erythrocyte Total PPIX Concentrations
Percent ChangePlaceboDISC-1459 Oral Low DoseDISC-1459 Oral High Dose
Erythrocyte Total PPIX Concentrations19.3 ± 59.95-20.5 ± 29.73-39.9 ± 34.67
SecondaryPlasma Total PPIX Concentrations

Percent change from baseline in plasma total PPIX concentration was summarized by analysis visit in the ITT population.

Time frame:
121 days
Reported as:
Mean · Percent Change
Plasma Total PPIX Concentrations
Percent ChangePlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose Level
Plasma Total PPIX Concentrations11.7 ± 56.76-45.4 ± 23.86-53.9 ± 31.55
SecondaryWhole Blood Total PPIX Concentrations

Percent change from baseline in whole blood total PPIX concentration was summarized by analysis visit in the ITT population.

Time frame:
121 days
Reported as:
Mean · Percent Change
Whole Blood Total PPIX Concentrations
Percent ChangePlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose Level
Whole Blood Total PPIX Concentrations8.2 ± 41.19-19.7 ± 31.71-40.1 ± 28.89
SecondaryPlasma Bitopertin Concentrations

Day 29 plasma bitopertin concentrations, 4 hours post-dose

Time frame:
Day 29
Reported as:
Mean · ng/mL
Plasma Bitopertin Concentrations
ng/mLDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose LevelPlacebo
Plasma Bitopertin Concentrations207.3 ± 83.5683.4 ± 308.8—

Adverse events

Collected over 121 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/24 (0%)1/24 (4.2%)19/24 (79.2%)
DISC-1459 Oral Low Dose Level0/26 (0%)0/26 (0%)19/26 (73.1%)
DISC-1459 Oral High Dose Level0/25 (0%)0/25 (0%)22/25 (88%)
Most frequent serious events
Most frequent serious events
EventPlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose Level
acute biliary pancreatitisGastrointestinal disorders1/240/260/25
Most frequent other events
Most frequent other events
EventPlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose Level
DizzinessNervous system disorders3/244/2611/25
NauseaGastrointestinal disorders4/241/264/25
HeadacheNervous system disorders3/243/262/25
Alanine aminotransferase increasedInvestigations3/241/262/25
FatigueGeneral disorders3/242/260/25
Blood iron increasedInvestigations0/242/263/25
DiarrhoeaGastrointestinal disorders2/241/261/25
COVID-19Infections and infestations2/242/261/25
Aspartate aminotransferase increasedInvestigations1/241/262/25
Transferrin saturation increasedInvestigations0/242/262/25

Baseline characteristics

Age, Customized
Age, Customized(years)PlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose LevelTotal
Age42.3 ± 12.2445.0 ± 14.3147.8 ± 14.0245.1 ± 13.58
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose LevelTotal
Female12141238
Male12121337
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose LevelTotal
Hispanic or Latino2024
Not Hispanic or Latino22262371
Unknown or Not Reported0000
Whole Blood Metal-free PPIX
Whole Blood Metal-free PPIX(ng/mL)PlaceboDISC-1459 Oral Low Dose LevelDISC-1459 Oral High Dose LevelTotal
Mean8691.0 ± 424.568154.6 ± 6816.4910597.0 ± 4916.249140.4 ± 5544.78
08

Study locations

9 sites
  • University of Alabama Hospital
    Birmingham, Alabama 35233, United States
  • University of California San Francisco
    San Francisco, California 94117, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Atrium Health Wake Forest Baptist
    Winston-Salem, North Carolina 27157, United States
  • Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • University of Texas
    Galveston, Texas 77550, United States
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Feb 2024, 15 months.

Results were first posted in Jan 2026, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2022
First posted
Apr 4, 2022
StartActual
Oct 31, 2022
Primary completionActual
Feb 20, 2024
CompletionActual
Aug 23, 2024
Results first posted
Jan 8, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05308472
Lead sponsor
Disc Medicine, Inc
Responsible party
Sponsor
First posted
Apr 4, 2022
Start date
Oct 31, 2022
Primary completion
Feb 20, 2024
Completion
Aug 23, 2024
Results posted
Jan 8, 2026
Last update
Jan 8, 2026

Study contacts

Will Savage, MD PhD
study director · Disc Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion